STEVEN M ALBELDA
Medical Practice in Philadelphia, PA
License number
Pennsylvania MD024774E
Category
Medicine
Type
Medical Physician and Surgeon
Address
Address
Philadelphia, PA 19103
Personal information
See more information about STEVEN M ALBELDA at radaris.comName
Address
Phone
135 S 19Th St Ofc O, Philadelphia, PA 19103
34 E Walnut Ln, Philadelphia, PA 19144
24 Penarth Rd, Bala Cynwyd, PA 19004
34 Walnut St, Philadelphia, PA 19144
135 S 19Th St #1611, Philadelphia, PA 19103
Professional information
Steven M Albelda, Philadelphia PA
Specialties:
Pulmonologist
Address:
3400 Spruce St, Philadelphia, PA 19104
Education:
University of Pennsylvania, Perelman School of Medicine - Doctor of Medicine
Hospital of the University of Pennsylvania - Fellowship - Pulmonary Disease (Internal Medicine)
Hospital of the University of Pennsylvania - Residency - Internal Medicine
Hospital of the University of Pennsylvania - Fellowship - Pulmonary Disease (Internal Medicine)
Hospital of the University of Pennsylvania - Residency - Internal Medicine
Board certifications:
American Board of Internal Medicine Certification in Internal Medicine, American Board of Internal Medicine Sub-certificate in Critical Care Medicine (Internal Medicine), American Board of Internal Medicine Sub-certificate in Pulmonary Disease (Internal Medicine)
Professor Of Medicine At University Of Pennsylvania
Position:
Professor of Medicine at University of Pennsylvania
Location:
Greater Philadelphia Area
Industry:
Research
Work:
University of Pennsylvania
-
Professor of Medicine
Steven Albelda, Philadelphia PA
Work:
Hospital of the University of PA
3400 Spruce St, Philadelphia, PA 19104 Penn. Lung Center
3400 Civic Center Blvd, Philadelphia, PA 19104
3400 Spruce St, Philadelphia, PA 19104 Penn. Lung Center
3400 Civic Center Blvd, Philadelphia, PA 19104
Professor At University Of Pennsylvania
Location:
Greater Philadelphia Area
Industry:
Medical Practice
Experience:
University of Pennsylvania (Educational Institution; 10,001+ employees; Medical Practice industry): Professor, (-)
Dr. Steven M Albelda, Philadelphia PA - MD (Doctor of Medicine)
Specialties:
Critical Care Medicine, Pulmonology
Address:
EAST PAVILION
3400 Civic Center Blvd SUITE 1ST, Philadelphia 19104
(215) 662-2450 (Phone)
UNIVERSITY OF PA MEDICAL CTR
3400 Spruce St SUITE F, Philadelphia 19104
(215) 662-4000 (Phone), (215) 349-8432 (Fax)
3400 Civic Center Blvd SUITE 1ST, Philadelphia 19104
(215) 662-2450 (Phone)
UNIVERSITY OF PA MEDICAL CTR
3400 Spruce St SUITE F, Philadelphia 19104
(215) 662-4000 (Phone), (215) 349-8432 (Fax)
Certifications:
Critical Care Medicine, 1987, Internal Medicine, 1982, Pulmonary Disease, 1984
Awards:
Healthgrades Honor Roll
Languages:
English
Hospitals:
EAST PAVILION
3400 Civic Center Blvd SUITE 1ST, Philadelphia 19104
UNIVERSITY OF PA MEDICAL CTR
3400 Spruce St SUITE F, Philadelphia 19104
Hospital of the University of Pennsylvania
3400 Spruce St, Philadelphia 19104
3400 Civic Center Blvd SUITE 1ST, Philadelphia 19104
UNIVERSITY OF PA MEDICAL CTR
3400 Spruce St SUITE F, Philadelphia 19104
Hospital of the University of Pennsylvania
3400 Spruce St, Philadelphia 19104
Education:
Medical School
Perelman School of Medicine University of Pennsylvania
Graduated: 1979
Hospital Of The University Of Pennsylvania
Perelman School of Medicine University of Pennsylvania
Graduated: 1979
Hospital Of The University Of Pennsylvania
Compositions Containing Thrombomodulin Domains And Uses Thereof
US Patent:
2011026, Oct 27, 2011
Filed:
Oct 16, 2009
Appl. No.:
13/124295
Inventors:
Vladimir R. Muzykantov - Warwick PA, US
Douglas B. Cines - Wynnewood PA, US
Claudia Gottstein - Carpinteria CA, US
Steven M. Albelda - Philadelphia PA, US
Douglas B. Cines - Wynnewood PA, US
Claudia Gottstein - Carpinteria CA, US
Steven M. Albelda - Philadelphia PA, US
Assignee:
The Trustees of the University of Pennsylvania - Philadelphia PA
International Classification:
A61K 39/395, A61P 7/02, A61P 7/10, A61P 29/00, A61P 9/10, C07K 19/00, A61P 11/00
US Classification:
4241781, 5303917
Abstract:
Compositions are provided comprising a thrombomodulin domain linked to a targeting moiety that binds to a determinant on the surface of a target endothelial cell or red blood cell, wherein the thrombomodulin domain may be the extracellular domain, the N-terminal lectin-like domain, or an epidermal growth factor (EGF)-like domain. The targeting moiety may be a single chain antigen-binding domain (scFv), and the targeting moiety and thrombomodulin domain of the composition may be linked as a continuous polypeptide chain. Methods of delivery and use of a composition described herein are provided, as well as methods of treating or preventing thrombosis, inflammation, tissue ischemia, sepsis, acute lung injury (ALI), acute myocardial infarction (AMI), ischemic stroke, cerebrovascular disease, pulmonary embolism, or ischemic peripheral vascular disease is provided.
Compositions And Methods For Treating Foxp3+ Treg Related Diseases
US Patent:
2013032, Dec 5, 2013
Filed:
Dec 1, 2011
Appl. No.:
13/991271
Inventors:
Wayne W. Hancock - Philadelphia PA, US
Steven M. Albelda - Philadelphia PA, US
Philip A. Cole - Baltimore MD, US
Steven M. Albelda - Philadelphia PA, US
Philip A. Cole - Baltimore MD, US
Assignee:
THE CHILDREN'S HOSPITAL OF PHILADELPHIA - Philadelphia PA
THE JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE - Baltimore MD
THE TRUSTEES OF THE UNIVERSITY OF PENNSYLVANIA - Philadelphia PA
THE JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE - Baltimore MD
THE TRUSTEES OF THE UNIVERSITY OF PENNSYLVANIA - Philadelphia PA
International Classification:
A61K 31/4155, A61K 38/16, A61K 31/7076, A61K 39/00
US Classification:
4242771, 514404, 424 943, 514 193, 514 47, 514 194, 514 195, 5483657, 530326, 536 2623, 435 32
Abstract:
Methods for treating or preventing a Foxp3+ T regulatory cell (Treg) related disease in a subject in need thereof comprise administering to the subject an effective amount of a pharmaceutical composition comprising an inhibitor of a histone/protein acetyltransferase (HAT). Methods for identifying an agent useful for treating or preventing a Foxp3+ T regulatory cell (Treg) related disease comprise (a) contacting a candidate agent with a test sample comprising Foxp3+ T regulatory cells (Tregs), and (b) comparing a function of the Foxp3+ Tregs in the test sample with that in a control sample, wherein inhibition of the function of the Foxp3+ Tregs in the test sample when compared with the control sample indicates that the candidate agent is an agent useful for treating or preventing a Foxp3+ Treg related disease.
Treatment Of Non-Neuronal Cancer Using Hsv-1 Variants
US Patent:
2011019, Aug 11, 2011
Filed:
Apr 20, 2011
Appl. No.:
13/090983
Inventors:
Susanne M. Brown - Glasgow, GB
Alasdair R. Maclean - Glasgow, GB
Nigel W. Fraser - Philadelphia PA, US
Bruce P. Randazzo - Philadelphia PA, US
Steven Albelda - Philadelphia PA, US
Larry Kaiser - Philadelphia PA, US
John Kucharczuk - Philadelphia PA, US
Alasdair R. Maclean - Glasgow, GB
Nigel W. Fraser - Philadelphia PA, US
Bruce P. Randazzo - Philadelphia PA, US
Steven Albelda - Philadelphia PA, US
Larry Kaiser - Philadelphia PA, US
John Kucharczuk - Philadelphia PA, US
Assignee:
THE TRUSTEES OF THE UNIVERSITY OF PENNSYLVANIA - Philadelphia PA
CRUSADE LABORATORIES LIMITED - Aldwych
WISTAR INSTITUTE - Philadelphia PA
CRUSADE LABORATORIES LIMITED - Aldwych
WISTAR INSTITUTE - Philadelphia PA
International Classification:
A61K 35/76, A61P 35/00, A61P 35/04
US Classification:
424 936
Abstract:
A mutant herpes simplex virus which has been modified in the γ34.5 gene such that the gene is non-functional is used to treat a non-neuronal cancer such as a mesothelioma, ovarian carcinoma, bladder cancer or melanoma. Typically, the mutant herpes simplex virus has been modified within the BamHI restriction fragment of the long terminal repeat of the viral genome.
Treatment Of Non-Neuronal Cancer Using Hsv-1 Variants
US Patent:
2007029, Dec 20, 2007
Filed:
Jun 19, 2007
Appl. No.:
11/765189
Inventors:
Susanne Brown - Glasgow, GB
Alasdair Maclean - Glasgow, GB
Nigel Fraser - Philadelphia PA, US
Bruce Randazzo - Philadelphia PA, US
Steven Albelda - Philadelphia PA, US
Larry Kaiser - Philadelphia PA, US
John Kucharczuk - Philadelphia PA, US
Alasdair Maclean - Glasgow, GB
Nigel Fraser - Philadelphia PA, US
Bruce Randazzo - Philadelphia PA, US
Steven Albelda - Philadelphia PA, US
Larry Kaiser - Philadelphia PA, US
John Kucharczuk - Philadelphia PA, US
International Classification:
A61K 48/00, A61P 35/04
US Classification:
424093200
Abstract:
A mutant herpes simplex virus which has been modified in the γ34.5 gene such that the gene is non-functional is used to treat a non-neuronal cancer such as a mesothelioma, ovarian carcinoma, bladder cancer or melanoma. Typically, the mutant herpes simplex virus has been modified within the BamHI restriction fragment of the long terminal repeat of the viral genome.
Treatment Of Non-Neuronal Cancer Using Hsv-1 Variants
US Patent:
2005022, Oct 13, 2005
Filed:
Jun 8, 2005
Appl. No.:
11/148575
Inventors:
Susanne Brown - Glasgow, GB
Alasdair MacLean - Glasgow, GB
Nigel Fraser - Philadelphia PA, US
Bruce Randazzo - Philadelphia PA, US
Steven Albelda - Philadelphia PA, US
Larry Kaiser - Philadelphia PA, US
John Kucharczuk - Philadelphia PA, US
Alasdair MacLean - Glasgow, GB
Nigel Fraser - Philadelphia PA, US
Bruce Randazzo - Philadelphia PA, US
Steven Albelda - Philadelphia PA, US
Larry Kaiser - Philadelphia PA, US
John Kucharczuk - Philadelphia PA, US
International Classification:
A61K048/00
US Classification:
424093200
Abstract:
A mutant herpes simplex virus which has been modified in the γ34.5 gene such that the gene is non-functional is used to treat a non-neuronal cancer such as a mesothelioma, ovarian carcinoma, bladder cancer or melanoma. Typically, the mutant herpes simplex virus has been modified within the BamHI restriction fragment of the long terminal repeat of the viral genome.